scholarly journals Renal Angiotensinogen and Sodium-Glucose Cotransporter-2 Inhibition: Insights from Experimental Diabetic Kidney Disease

2019 ◽  
Vol 49 (4) ◽  
pp. 328-330 ◽  
Author(s):  
Kevin D. Burns ◽  
David Cherney
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Diabetic Kidney ◽  
Sodium Glucose Cotransporter

scholarly journals Erratum. Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease. Diabetes 2019;68:248–257

Diabetes ◽  
2019 ◽  
Vol 68 (5) ◽  
pp. 1094-1094
Author(s):  
Radica Z. Alicic ◽  
Joshua J. Neumiller ◽  
Emily J. Johnson ◽  
Brad Dieter ◽  
Katherine R. Tuttle
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Diabetic Kidney ◽  
Sodium Glucose Cotransporter

scholarly journals Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease

2020 ◽  
Vol 35 (Supplement_1) ◽  
pp. i13-i23 ◽  
Author(s):  
Jose Luis Górriz ◽  
Juan F Navarro-González ◽  
Alberto Ortiz ◽  
Ander Vergara ◽  
Julio Nuñez ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Safety Management ◽  
Blood Glucose Control ◽  
European Medicines Agency ◽  
Diabetic Patients ◽  
Diabetic Kidney ◽  
Renin Angiotensin ◽  
Sodium Glucose Cotransporter

Abstract Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have clearly demonstrated their beneficial effect in diabetic kidney disease (DKD) on top of the standard of care [blood glucose control, renin–angiotensin system blockade, smoking cessation and blood pressure (BP) control], even in patients with overt DKD. However, the indication of this drug class is still blood glucose lowering in type 2 diabetic patients with estimated glomerular filtration rate >45 mL/min/1.73 m2. Based on the new evidence, several scientific societies have emphasized the preferential prescription of SGLT2i for patients at risk of heart failure or kidney disease, but still within the limits set by health authorities. A rapid positioning of both the European Medicines Agency and the US Food and Drug Administration will allow patients with overt DKD to benefit from SGLT2i. Clinical experience suggests that SGLT2i safety management may in part mirror renin–angiotensin blockade safety management in patients with overt DKD. This review focuses on the rationale for an indication of SGTL2i in DKD. We further propose clinical steps for maximizing the safety of SGLT2i in DKD patients on other antidiabetic, BP or diuretic medication.

scholarly journals Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease

Diabetes ◽  
2019 ◽  
Vol 68 (2) ◽  
pp. 248-257 ◽  
Author(s):  
Radica Z. Alicic ◽  
Joshua J. Neumiller ◽  
Emily J. Johnson ◽  
Brad Dieter ◽  
Katherine R. Tuttle
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Diabetic Kidney ◽  
Sodium Glucose Cotransporter

scholarly journals Glomerular Diseases in Diabetic Patients: Implications for Diagnosis and Management

2021 ◽  
Vol 10 (9) ◽  
pp. 1855
Author(s):  
Nestor Oliva-Damaso ◽  
José María Mora-Gutiérrez ◽  
Andrew S. Bomback
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Treatment Strategies ◽  
Glomerular Disease ◽  
Diabetic Patients ◽  
Glomerular Diseases ◽  
Diabetic Kidney ◽  
Sodium Glucose Cotransporter ◽  
Patients With Diabetes ◽  
New Treatment

The prevalence of diabetes continues to rise worldwide. In addition to rising rates of diabetic kidney disease, we are also seeing a parallel rise in nondiabetic kidney disease among patients with diabetes. These nondiabetic lesions include focal segmental glomerulosclerosis, IgA nephropathy, membranous nephropathy, and other glomerular diseases. The management of diabetic kidney disease is rapidly evolving to include, beyond glycemic control and renin angiotensin inhibition, the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists. These and other new treatment strategies should be applicable to managing glomerular disease in diabetic patients to reduce toxicities associated with immunosuppression and, in particular, corticosteroids. The prevalence of glomerular disease in diabetic patients is underappreciated. Diagnosis and appropriately treating these diseases remain an important avenue to modify kidney outcomes in diabetic patients.

Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Mohanad Almaimani ◽  
Vikas S. Sridhar ◽  
David Z.I. Cherney
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Diabetic Kidney ◽  
Sodium Glucose Cotransporter
Sign in / Sign up

Export Citation Format

Share Document